A Phase I Trial of Single-Agent LY2780301 in Patients With Advanced or Metastatic Cancer.

Trial Profile

A Phase I Trial of Single-Agent LY2780301 in Patients With Advanced or Metastatic Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2015

At a glance

  • Drugs LY 2780301 (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.as reported by ClinicalTrials.gov.
    • 30 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 02 Jul 2012 Planned End Date changed from 1 May 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top